Tetraphase Pharmaceuticalsincwas A Clinical Stage Biopharmaceutical Company Based In Walthammassachusettsfounded In 2006The Company Focused On Developing Novel Tetracycline Class Antibiotics To Combat Multidrug Resistant Bacterial Infectionsparticularly Those Identified As Urgent Public Health Threats By The Who And Cdctetraphase Utilized A Proprietary Chemistry Platform To Create Structurally Diverse Tetracycline Analogsenhancing Efficacy Against Resistant Pathogensits Lead Candidates Included Eravacyclineaimed At Treating Complicated Intra Abdominal Infectionsand Tp 6076Targeting Carbapenem Resistant Bacterial Infectionsin July 2020Tetraphase Was Acquired By La Jolla Pharmaceutical Companywhich Integrated Its Operations And Pipeline Into Its Own Infrastructureexpanding Its Infectious Disease Portfolio
